Q2 2026 saw robust revenue growth, strong U.S. and international demand for VYJUVEK, and progress in clinical and regulatory milestones. Net revenue rose 24% year-over-year, with over 730 U.S. reimbursement approvals and continued global expansion.Based on Krystal Biotech, Inc. [KRYS] Q2 2026 Audio…
Q2 2026 saw strong revenue growth, robust U.S. commercial performance, and expanding international demand for VYJUVEK, despite flat European revenues due to German pricing accruals. The pipeline advanced with multiple registrational studies nearing readouts and a strong cash position supporting fut…
PITTSBURGH, July 23, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) NASDAQ:KRYS announced today that it will report its second quarter 2026 financial results on Monday, August 3, 2026, prior to the open of U.S. markets.The Company’s management will also host a conference call and we…
